



PRESS RELEASE

to-BBB announces research collaboration with Biogen Idec

Leiden, The Netherlands - March 14, 2005 - The Dutch biotechnology company to-BBB announced a research collaboration agreement today with Biogen Idec (NASDAQ: BIIB) on the basis of to-BBB's drug targeting technology, 2B-Trans™. With the 2B-Trans™ technology it is possible to deliver drugs to the central nervous system.

The two companies will investigate whether the technology can deliver a protein of interest to Biogen Idec to the central nervous system (CNS). to-BBB is pleased with the collaboration with Biogen Idec: "The agreement is an important step for to-BBB to show its potential as a CNS drug targeting company," said Dr. Pieter Gaillard, Chief Executive Officer of to-BBB.

For the collaboration to-BBB was granted an Innovation Subsidy for Collaborative projects from the Dutch Ministry of Economic Affairs. The grant includes matching finance for the upcoming two years. Further financial details were not disclosed.

About 2B-Trans™ technology

The CNS drug market is a rapidly growing market. However, many potential CNS drugs cannot enter the brain due to the presence of the neuroprotective blood-brain barrier. to-BBB developed the unique CNS drug targeting solution 2B-Trans™ that delivers drugs into the CNS after an intravenous injection, without disruption of the blood-brain barrier. The proprietary 2B-Trans™ technology uses a well characterized and effective transport system with a specific carrier protein that has an excellent proven safety profile in human.



About to-BBB technologies BV

to-BBB, founded in 2003, is a spin-off company from the renowned Blood-Brain Barrier Research Group of Leiden University in The Netherlands. to-BBB is located at the Bio-Science Park in Leiden.

to-BBB has signed collaboration and development agreements with two US based top five biotech companies and is currently negotiating agreements with several other companies that will be offered access to the 2B-Trans™ technology. For additional information about the company, please visit www.toBBB.com.

For further information please contact:

Alfred N. Nijkerk, PharmD, CBO

Tel: +31 6 55128387

Fax: +31 84 8709728

E-mail: Nijkerk@toBBB.com

Website: www.toBBB.com